Modeling the impact of spatial inequities in access to medications for treatment of opioid use disorder among persons who inject drugs

Eric Tatara (1), Qinyun Lin (2), Jonathan Ozik (1), Marynia Kolak (2), Nicholson Collier (1), Dylan Halpern (2), Luc Anselin (2), Harel Dahari (3), Basmattee Boodram (4), John Schneider (5)

(1) Decision and Infrastructure Sciences Division, Argonne National Laboratory and Consortium for Advanced Science and Engineering, University of Chicago
(2) Center for Spatial Data Science, University of Chicago
(3) Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago
(4) Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago
(5) Department of Infectious Disease, UChicago Medicine

Declarations of competing interest: None of the authors have any financial interest or conflict of interest related to this research.

Key words: MOUD, opioid use disorder, persons who inject drugs; agent-based modeling; methadone

ABSTRACT

Background: Access to treatment and medication for opioid use disorder (MOUD), such as methadone, is essential for improving health outcomes by reducing infection and overdose risks associated with injection drug use. MOUD resource distribution, however, is often a complex interplay of social and structural factors that result in nuanced patterns reflecting underlying social and spatial inequities. Persons who inject drugs (PWID) that receive MOUD treatment experience a reduction in the number of daily drug injections and a reduction in the number of syringe sharing episodes with other individuals. We assessed the impact on reduction in syringe sharing behaviors among PWID who are adherent to methadone treatment via simulation studies.

Methods: Actual (real-world) and counterfactual scenarios of varying levels of social and spatial inequity to providers of methadone were evaluated using HepCEP, a validated agent-based model of syringe sharing behaviors among people who inject drugs (PWID) in metropolitan Chicago, Illinois, U.S.A. Synthetic spatial distributions reflecting disparate geographic patterns of methadone provider location and population characteristics are evaluated to show how population-level health outcomes vary accordingly.

Results: For all methadone access assumptions and provider location distributions, redistributing methadone providers results in some areas with poor access to MOUDs. All scenarios exhibited some areas with poor access, highlighting the scarcity of providers in the region as a major challenge. Need-based distributions are more like the actual provider distribution, indicating that the actual spatial distribution of methadone providers already reflects the local need for MOUD resources.

Conclusions: The impact of the spatial distribution of methadone providers on syringe sharing frequency is dependent on access. When there are significant structural barriers to accessing methadone providers, distributing providers near areas that have the greatest need (as defined by density of PWID) is optimal.

INTRODUCTION

Access to treatment and medication for opioid use disorder (MOUD) is essential for improving health outcomes by reducing risks for HIV and HCV infection and overdose associated with injection drug use [1–3]. In addition to individual competing priorities (e.g., unstable housing, childcare), barriers to access to MOUD among PWID may include structural factors (e.g., drug use-related stigma [4], transportation, and long travel distances). In Illinois, buprenorphine providers are more widely available; however, this is not the case with methadone, which some studies have shown has racial/ethnic disparities. Historical, socioeconomic, racial, and other structural factors influence both availability and perception of MOUDs [5]. Furthermore, distinct differences in MOUD pharmacology, delivery, and patient preference exist. As a golden standard to address inequities, MOUDs should be available in all communities to facilitate treatment individualization and support retention [6] though methadone persistently tends to have the worst geographic access despite high success rates in preventing overdose [7]. As such, understanding access to methadone, health services, and other harm reduction services (e.g., naloxone, syringe service programs) is critical to defining risk environment landscapes that affect fatal and nonfatal overdoses and HIV and HCV infections related to injection drug use.

Effective prevention and treatment strategies exist for OUD but are highly underutilized across the United States. Indeed, only a small fraction (11%) who need medication for opioid use disorder (MOUD) received it in 2020 [8]. Methadone, a synthetic opioid agonist that eliminates withdrawal symptoms and relieves drug cravings by acting on opioid receptors in the brain, is the medication with the longest history of use for OUD treatment, having been used since 1947. A large number of studies support methadone's effectiveness at reducing opioid use [9]. While expedient access to methadone maintenance treatment is critical to preventing overdose death [7], at this time its provisioning is restricted to licensed opioid treatment provider locations. While buprenorphine access has increased across the US due in part to fewer restrictions, people with SUD deserve options for treatment and

many patients prefer methadone even with the barriers to geographic location: a factor that motivates the current analysis [10].

Our study examines the effects of methadone provider distribution in Chicago and the surrounding suburbs within Illinois, U.S.A. on IDU risk mitigation (i.e., reduction in syringe sharing) among PWID, which is often a function of the complex interplay of historical, sociological, and structural factors, resulting in nuanced patterns that reflect underlying social and spatial inequities. Research on access to primary health services often cite a preference for a less than 30-minute travel time for individuals seeking care [11,12], though in a survey of Opioid Treatment Programs in 2010, almost 60% of outpatients had to travel over an hour for services (HHS 2010). Two decades later, more than a third of continental U.S. zip codes are more than an hour away from treatment, and access to methadone providers remains worse than other MOUD types (ex. buprenorphine and naltrexone) [13]. Providing transportation services has been shown to improve treatment retention for methadone maintenance programs and outpatient drug-free programs [14]. Minoritized racial/ethnic status has been associated with admission delays for outpatient methadone treatment [6] and reduced likelihood of being offered pharmacologic support for recovery [15] – though once engaged in treatment, have similar retention rates to the majority of clients [16]. At the same time, minority groups may prefer accessing treatment services within primary care settings versus specialty mental health clinics [17]. While geographic access is crucial, access is a multidimensional concept that can be deconstructed into the components of availability, accommodation, affordability, and acceptability [18]. For persons with OUD, access is especially complex because of the interplay of MOUD resource scarcity and drug use stigma, as patients experiencing stigma at MOUD providers are less likely to return [19].

Measuring spatial access to public resources must consider the frequency of resource utilization and the mode of transit to the resource [20]. Travel hardships, including extended distances, longer

travel, and interstate commute, have been considered as the most common accessibility barriers for people who seek care from distant providers, especially for persons in rural areas where public transportation is limited [21–23]. Most existing studies focus on *actual* distance to MOUD locations and very few have studied what is the *ideal* distance (or travel time) preferences to ensure accessibility. The effect of travel hardships on accessibility is most critical for methadone considering the need for daily dosing. Increased distance to treatment can impede daily attendance as shown in a recent study of patients receiving MOUD treatment that found that patients residing 10 miles from the treatment facility were more likely to miss doses compared to those who lived within 5 miles [24]. Furthermore, the frequency of *scheduled* treatment appointments versus *received* treatment can differ. For example, in related work that focuses on access to HIV care, there was a trend towards making appointments, but actual medication adherence was not impacted [25], nor was living in an area with high rates of crime. Conventional interventional trials test whether modification of spatial factors is needed, but often difficult and costly to implement.

There is a need for more rapid approaches to assessing and translating spatial epidemiologic findings to practical real-world interventions. In this paper, we examine the impact of methadone provider distribution on syringe sharing among PWID from Chicago and the surrounding suburbs using a validated agent-based model (ABM) (Hepatitis C Elimination in Persons Who Inject Drugs or HepCEP) [2]. Our modeling approach accounts for uncertainties in how individuals perceive access to methadone providers and how that perception affects their decisions to initiate and adhere to MOUD treatment. As such, we employ a robust decision making perspective [26] to capture the effects of different methadone provider distribution approaches across these uncertainties.

METHODS

HepCEP Model

Our current study extends previous work on simulating the PWID population in Chicago and the surrounding suburbs, Illinois, USA, including drug use and syringe sharing behaviors, and associated infection dynamics [22,24]. The demographic, behavioral and social characteristics of the PWID population is generated using data from five empirical datasets on metropolitan Chicago (urban and suburban) area PWID that is previously described [27]. In brief, this includes data from a large syringe service program (SSP) enrollees (n=6,000, 2006-13) [28], the IDU data collection cycles of the National HIV Behavioral Surveillance (NHBS) survey from 2009 (n=545) [29] and 2012 (n=209) [30], and a social network and geography study of young (ages 18-30) PWID (n=164) [31]. Data analyses from these sources is used to generate attributes for each of the estimated 32,000 PWID in the synthetic population for metropolitan Chicago [32] in the model and includes: age, age of initiation into injection drug use, gender, race/ethnicity, zip code of residence, HCV infection status, drug sharing network degree, parameters for daily injection and syringe sharing rates, and harm reduction/syringe service program (SSP) enrollment [27]. PWID agents may leave the population due to age-dependent death or drug use cessation and are replaced with new PWID sampled from the input data set to maintain a nearly constant population size of 32,000 for the entire course of the simulation.

Syringe sharing among PWID is modeled in HepCEP via dynamic syringe sharing networks. Network formation is determined by the probability of two PWID encountering each other in their neighborhood of residence and within the outdoor drug market areas in Chicago that attracts both urban and non-urban PWID for drug purchasing and utilization of SSPs that are also located in the same areas [33]. The methods used to calculate network encounter rates, establishment processes, and removal of networks have been described previously [27]. Each modeled individual has an estimated number of in-network PWID partners who give syringes to the individual and out-network PWID

partners who receive syringes from the individual. The network edge direction determines the flow of

contaminated syringes between individuals, and thus the direction of disease transmission. The network

evolves, and during the course of simulation some connections (ties) may be lost, while new ties form,

resulting in an approximately constant network size.

MOUD treatment enrollment is modeled in two steps. First, there is an unbiased awareness of

MOUD resources by PWID, capturing the knowledge that agents possess about the existence of a

methadone provider. The annual target awareness rate, defined as the total annual awareness as a

fraction of the total population, is a model parameter with a constant value of 90%. Thus, over the

course of a year, 90% of the PWID population will be made aware of MOUD treatment and,

subsequently decide whether to engage in MOUD treatment. The total PWID target MOUD treatment

awareness for a single day is determined by the daily mean treatment awareness, which is the total

PWID population multiplied by the annual treatment awareness parameter / 365. The daily awareness

target is sampled from a Poisson distribution using the daily mean treatment awareness.

PWID that receive MOUD treatment experience a reduction in the number of daily drug

injections, which is determined by multiplying the PWID's baseline pre-MOUD daily drug injection

frequency by a reduction multiplier sampled from a uniform distribution from 0 to 0.25 [34]. Thus, the

mean reduction in daily injection frequency is 87% when on MOUD treatment compared to when not on

MOUD. Reduction in daily injection frequency reduces the number of syringe sharing episodes with

other infected individuals.

Reasonable Geographic Access Assumptions

The decision to initiate MOUD treatment is entirely dependent on the travel distance to the nearest

methadone provider from the PWID place of residence. PWID first decide to enroll in treatment and

then repeatedly decide to continue treatment every 7 days, a duration chosen to reflect the average

frequency of clinic visits for the treatment over time. Average overall treatment duration for methadone is obtained from literature to be 150 days [35] and different urban and non-urban travel distance preferences to the nearest methadone provider are used by PWID to determine if they will or will not enroll in MOUD treatment (Table 1). The probability that a PWID will enroll in MOUD treatment is greater when the treatment travel distance is below the travel distance preference.

We define six different possible combinations of low, medium, and high travel distance preferences considering three urban/suburban distance preference combinations for each low, medium, high travel distance preference pair with a maximum travel distance preference, and three corresponding low, medium, and high travel distance preferences pairs with no maximum distance preference (Table 1). In the cases with maximum preferences, the individuals will not be able to access treatment if the provider is farther away than the maximum preferred travel distance.

To approximate reasonable geographic access, the travel distance in miles from zip code centroid to the nearest methadone provider is calculated using the *sf* package in R (version 4.0.2) [36]. Methadone treatment requires frequency of visits comparable to that of people's grocery shopping (daily or weekly) [37,38], and travel distances of 1 mile (urban) and 10 miles (suburban/rural) areas is reasonable for community members, respectively, to their grocery stores. Because of the scarcity of methadone providers, we extend the urban reasonable travel distance preference to 2 miles. Published findings indicate that access to mental health treatment within 10 miles is associated with greater attendance in persons with OUD [39]. Accordingly, the travel distance preference of "reasonable geographic access" to the methadone provider is set at 2 miles, which approximates a 30-minute walking distance in urban areas, and for suburban and rural areas, the travel distance preference is set at 10 miles (Table 1).

As there is limited information on how geographic access affects individuals' decision to seek treatment, an additional layer of uncertainty is introduced via penalties on individuals' probability of getting treatment when the geographic travel distance exceeds the reasonable access distance preference but is below the maximum distance limit. If the travel distance exceeds the preference, the per-decision probability of treatment is lower (by a factor θ) than if the PWID is closer to the provider. Since θ is not easily estimated, values are chosen ranging from 60% to 90% for this study, which represents broad per-decision penalties for accessing locations beyond distance preferences. The base probabilities are calculated by using the distribution of the PWID agent population under the actual spatial distribution of methadone providers (see below) and under different preference scenarios to match the overall methadone treatment duration values. Each penalty level is combined with each of the six travel distance preference combinations in Table 1, resulting in 18 separate parameter combinations, or reasonable access assumptions.

Spatial Distribution of Methadone Providers

MOUD Provider Data

This study includes data on methadone maintenance MOUD providers in Chicago and the surrounding suburbs, which we define as the 298 zip codes from Cook County (i.e., the most populous county in Illinois and includes Chicago) and the five collar counties that border Cook, which are also the next five most populous counties in the state. We include providers beyond these boundaries for the state of Illinois to provide context in interpretation, though only perform simulations and evaluate scenarios within these boundaries. A total of 81 Illinois providers are identified by specifying "methadone maintenance" from the Substance Abuse and Mental Health Service Administration (SAMHSA) Behavioral Health Treatment Service Locator (derived from the 2019 National Survey of Substance Abuse Treatment Service) [40].

Counterfactual Methadone Provider Spatial Distributions

To study how the spatial distribution of methadone providers affects syringe sharing behaviors among PWID, three counterfactual distributions are generated to spatially redistribute methadone provider locations. That is, the geographic locations of methadone providers are changed and re-evaluated for accessibility to those providers. In all scenarios, the total number of all methadone providers in Illinois are assumed to be constant (n = 81).

Spatially random: MOUD treatment locations are randomly distributed within the study area (298 zip codes in Cook and five collar counties) and other areas (1085 zip codes) in Illinois. The total number of modelled methadone providers in Illinois remain unchanged, only the location of these resources changes. This distribution provides a useful null hypothesis of spatial randomness that can be benchmarked against actual geographic distribution of resources, as well as alternate counterfactual distributions.

Need-based 1: Methadone provider locations are assigned proportionally to the adult population (age 18-39) within each zip code which results in more methadone providers assigned to zip codes with larger adult populations. The "largest remainder method" is used to calculate the number of methadone providers assigned to each zip code and to ensure that each area was assigned an integer number of methadone providers. Specifically, methadone providers are first allocated to each zip code proportional to the local at-risk population. The result for each zip code consists of an integer part plus a fractional remainder, or in some cases, only a fractional remainder. Each zip code is first allocated an integer number of providers. This leaves some providers unallocated. The zip codes are then ranked based on the fractional remainders: one additional methadone provider is added to the zip code areas ranking the highest until all providers are allocated.

Need-based 2: In this distribution, methadone providers are assigned proportionally to the total PWID

population for each zip code (see Gutfraind et al. 2015 for PWID data) [27]. The difference between

Need-based 1 and *Need-based 2* is how the need for methadone within each zip code area is estimated.

Need-based 2 is potentially more accurate as the PWID population likely represents a closer

approximation for the need for methadone providers than an area's entire adult population.

Figure 1 presents the locations of methadone providers across three counterfactual distributions. In

general, the two *Need-based* counterfactual distributions are most like the real situation compared to

the spatially random distribution.

Outcome: Syringe sharing

The reduction in annual syringe sharing events among PWID who are adherent to methadone treatment

is investigated as the main outcome of interest of the simulation studies. Syringe sharing reduction and

the relative risk of syringe sharing are calculated for each of the 18 reasonable access assumptions in

each of the three counterfactual methadone provider distributions, along with the actual provider

distribution. A baseline is first conducted to determine the number of syringe sharing events in each zip

code when PWID have no awareness of methadone providers, and do not enroll in MOUD treatment.

The baseline is not sensitive to provider distribution or travel distance preference since no MOUD

treatment occurs.

For each combination of reasonable access assumption and provider distribution, the syringe

sharing reduction metric is defined as the difference in the number of annual syringe sharing episodes in

each zip code when PWID are aware of methadone providers, relative to the baseline. The HepCEP

model is run for a 20-year period starting in 2010 through simulated year 2030. The total number of

syringe sharing episodes in each zip code is tabulated only for year 2030, resulting in the metrics for

annual syringe sharing reduction. The simulation time frame is based on the need to initialize the model

using population data calibrated to year 2010, and to allow the model population and network dynamics

to stabilize, as has been done in prior studies [22,24].

A total of 1,440 simulations were conducted using high-performance computing workflows

implemented with the EMEWS framework [41]. The 1,440 runs include 20 stochastic replicates for each

of the 72 parameter sets, where each parameter set corresponds to the four provider spatial

distributions for each of the 18 reasonable access assumptions. We report the mean number of syringe

sharing episodes across the 20 stochastic replicates. The simulation experiments were executed on the

Bebop cluster run by the Laboratory Computing Resource Center at Argonne National Laboratory.

We aggregated the syringe sharing reduction metric across all zip codes to produce a single

scalar metric for each of the 72 parameter sets. A "regret" score is calculated, defined as how many

fewer syringe sharing episodes the scenario under consideration had compared to the best scenario

under a particular reasonable access assumption. Finally, to capture robustness in the spatial strategies,

i.e., adequate performance across reasonable access assumptions, the 75th-percentile of the regret

score distribution is reported. To understand the effects that differences in syringe sharing densities

across the zip codes might show, the analyses are repeated using the ratio of syringe sharing, i.e., the

risk ratio, for each zip code.

RESULTS

Spatial access to methadone providers under different reasonable geographic access assumptions

Figure 1 provides a geographic illustration of whether each zip code's minimum travel distance to a

methadone provider is within the travel distance preference of reasonable geographic access,

underlying different assumptions of what is the ideal distance to ensure accessibility. The first, second,

and third row in Figure 1 corresponds to the low, middle, and high travel distance preferences,

respectively in Table 1. For each trave distance preference (each row in Figure 1), the four figures

(columns in Figure 1) show each zip code's accessibility to the nearest methadone provider under the actual spatial distribution of providers and three counterfactual spatial distributions.

Consistent with Figure 1, the two need-based distributions are more like the actual provider distribution, irrespective of the travel distance preference, indicating that the actual spatial distribution of methadone providers already reflects the local need for MOUD resources. However, comparing the actual distribution with the two need-based distributions, we identify areas where the need for methadone providers is high while the spatial access to methadone providers is limited. For example, some areas in South Chicago have high needs but few providers, and accessibility to methadone providers are improved in the two need-based counterfactual distributions.

Comparing across rows in Figure 1, more zip codes have better spatial access to methadone providers as we assume a higher travel distance preference (i.e., people are able and willing to travel longer distances). This preference does not account for transit barriers such as travel time and access to public transit infrastructures, vehicles, as well as the financial cost of transit. Under the low travel distance preference that likely reflects real-world barriers to transit, few areas have reasonable geographical access to methadone providers. Therefore, simply spatially redistributing providers may not provide better access to providers when the number of individual providers is limited.

Spatial distribution of syringe sharing reduction

Because the total number of methadone providers are fixed in this analysis, redistributing provider locations in the counterfactual distributions relative to the actual distribution leads to some areas having a higher reduction in syringe sharing episodes than others, while some areas showed an increase in the number of syringe sharing episodes. Figure 2 shows the syringe sharing events reduction in each zip code under each reasonable access assumption for the actual distribution along with how the syringe sharing reduction changes if the methadone providers are spatially redistributed in counterfactual

distributions. Blue colored zip codes indicates that the counterfactual distribution has more reduction than the actual distribution (for the same zip code), while red colored zip codes indicate that the counterfactual distribution has less reduction than the actual distribution.

Comparing across different distributions, the syringe sharing reduction achieves the best result under the most optimistic reasonable access assumption conditions, which assumes the high travel distance preference, no travel distance maximum, and a penalty of 0.9 (see the first four maps in the last row in Figure 2). In this case, travel distance contributes the smallest effect in impacting the probability of continuing treatment or not. On the contrary, the last four maps in the first row (Figure 2) represent the most pessimistic reasonable access assumption conditions, which assumes the low travel distance preference with a maximum travel distance, and a high penalty of 0.6. As expected, the syringe sharing reduction is the lowest in this case.

Syringe sharing reduction under different provider distributions

Figure 3 provides a visual representation of the regret scores of annual reduction in syringe sharing episodes for each reasonable access assumption and spatial distribution of methadone providers. Each dot in Figure 3 represents the regret score for each of the 18 reasonable access assumptions, color coded by different assumptions of ideal geographical distance (See Appendix for Tables listing all these regret scores, along with syringe sharing reduction). Given the definition of regret scores, lower values represent a more ideal outcome (less regret), i.e., the closer the regret score is to 0 the more that the scenario under consideration is similar to the best scenario. Noticeably, the need-based 2 distribution performs better than the need-based 1 distribution when spatial access makes the most difference (i.e., low travel distance preference represented as orange dots), while the need-based 1 performs better than the need-based 2 distribution when spatial access makes a moderate to small impact (i.e., middle and high travel distance preference, represented as blue and green dots). Interestingly, the actual distribution performs better than the need-based 2 distribution when assuming spatial access makes the

least impact (i.e., high travel distance preference represented as green dots), while it performs much worse than both need-based distributions when assuming spatial access makes the most difference (i.e., low travel distance preference represented as orange dots). In all cases, the spatially random distribution generates the worst result.

DISCUSSION

Our agent-based model study of PWID from Chicago and the surrounding Illinois suburbs provides valuable insights into the development of future interventions to enhance MOUD treatment uptake by PWID. We found that the impact of the spatial distribution of methadone providers on syringe sharing frequency is dependent on assumptions of access. First, when there is a low travel distance preference for accessing methadone providers, meaning PWID populations are faced with significant structural barriers, distributing providers near areas that have the greatest need (defined by density of PWID) is optimal. However, this strategy also decreases access across suburban locales, posing even greater difficulty in regions with fewer transit options and providers. As such, without an adequate number of providers to give equitable coverage across the region, spatial distribution cannot be optimized to provide equitable access to all persons (and potential persons) with OUD. Policies that would expand geographic access to methadone maintenance treatment by making it available at pharmacies and/or federally qualified health centers may better meet the need of the population [42,43].

Second, the most optimal condition for a medium travel distance preference is a scenario based on allocating methadone providers by estimated PWID population density alone. Third, a salient finding is that the need-based 2 distribution performed better than other distributions in 14 out of 27 runs, or over half of the time. Ensuring providers are optimized in their locations closer to PWID populations was considered effective most of the time, when actual, true travel distance preferences are unknown. This may be a vulnerable position, however, as shutting down even one location—or persons avoiding a

location due to structural barriers (e.g., transit, stigma)--heightens the treatment provider scarcity, assuming a lower travel distance preference.

The PWID population in Chicago and the surrounding suburbs [44] and other urban areas [32] is well-characterized. Detailed and current knowledge on PWID demographics can be used to study how access to MOUD treatment providers can be improved over existing resource distributions, along with estimates of future needs due to shifts in PWID demographics and locations.

For all reasonable access assumptions and provider location distributions, redistributing methadone providers meant that some areas had worse access to MOUDs. There were no scenarios that exhibited zero areas with worse access, highlighting the scarcity of providers in the region as a major challenge. When mapping results, often more remote and less populated areas remained, reflecting the urban-rural accessibility challenges impacting populations in real life. For scenarios with larger tails, with some areas having significantly worse access, mobile treatment providers could be incorporated to target vulnerable populations.

Under scenarios with substantial uncertainties, particularly related to underlying individual behaviors that are difficult to observe, optimal interventions may not be the appropriate goal. Instead, robust interventions [26], which are specific interventions that perform well over a wide range of possible ground truths should be sought. Detailed, data-driven, agent-based models combined with the capacity for large-scale computational experimentation, can provide such analyses to support decision making under uncertainties, or when empirical data collection is costly or unethical.

Need-based counterfactuals were more similar to actual provider distributions than the spatially random scenario, suggesting some areas' needs are being met. However, some geographic locales remain in high need of resources, as demonstrated by the need-based scenarios. McHenry county, in the northeastern part of the study area, is notable for having all or most of its zip codes characterized by no access in all travel distance preference assumptions – despite a large adult and PWID population that

needs it. Many nearby suburban counties likewise have a patchwork of access across travel distance preference assumptions. While some regions of Chicago have access to providers, more access on transit-connected northern and lake coastal sides of the city would better support populations who currently need, or may need, treatment.

Distributions of actual methadone providers was reasonably close to where populations needed it, though much less access to the MOUDs with the best results in reducing mortality. The low travel distance preference assumption highlights multiple, significant gaps in access across the Chicago and the surrounding counties. While this assumption may seem restrictive, it may be the most realistic. For example, 1- and 5-miles traveled in urban or suburban areas for a resource required daily or weekly is considered exceptionally reasonable in food access literature (where grocery stores may also be accessed weekly). This low travel distance preference assumption may also be optimistic because of additional social, economic, and structural barriers faced at opioid treatment programs providing methadone services, like cost and drug use stigma (experienced at the provider and/or neighborhood that it is located within).

Limitations

Our current results report only reductions in syringe sharing episodes for all combinations of reasonable access assumption and provider spatial distributions. Our previous work focused on reduction of new chronic HCV infection [2] in the PWID population; however, the current study did not show significant associated reductions in HCV infection in most zip codes, even as the number of syringe sharing episodes are reduced compared to baseline (data not shown). The most likely explanation is that since the current study does not implement HCV treatment and other harm reduction (e.g., syringe services), simply reducing the syringe sharing frequency in a highly connected PWID network is not sufficient to eliminate new HCV infection without also reducing the disease incidence.

Second, the reported results include the annual reduction in syringe sharing for only a single simulation year. Time-varying trends in syringe sharing metrics were not investigated. Further, the PWID population is maintained at a constant size of 32,000 individuals for the course of the simulation. Although we model transient changes in PWID demographics as in previous studies [2,27], we believe that the PWID population size may be somewhat close to constant given that people who transition to MOUDs is balanced out by new initiates into IDU entering the population.

Acknowledgements

This work is supported by the National Institute on Drug Abuse grant U2CDA050098 (The Methodology and Advanced Analytics Resource Center), the National Institute of General Medical Sciences grant R01GM121600, by the U.S. Department of Energy under contract number DE-AC02-06CH11357, and was completed with resources provided by the Laboratory Computing Resource Center at Argonne National Laboratory (Bebop cluster). The research presented in this paper is that of the authors and does not necessarily reflect the position or policy of the National Institute on Drug Abuse or any other organization.

REFERENCES

1. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4: 435–444. doi:10.1016/S2468-1253(19)30085-8

2. Tatara E, Gutfraind A, Collier NT, Echevarria D, Cotler SJ, Major ME, et al. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. PLOS ONE. 2022;17: e0264983. doi:10.1371/journal.pone.0264983

3. Tatara E, Schneider J, Quasebarth M, Collier N, Pollack H, Boodram B, et al. Application of Distributed Agent-based Modeling to Investigate Opioid Use Outcomes in Justice Involved Populations. 2021 IEEE International Parallel and Distributed Processing Symposium Workshops (IPDPSW). 2021. pp. 989–997. doi:10.1109/IPDPSW52791.2021.00157

4. Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. Drug Alcohol Depend. 2021;221: 108626. doi:10.1016/j.drugalcdep.2021.108626

5. Andraka-Christou B. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. Health Aff (Millwood). 2021;40: 920–927. doi:10.1377/hlthaff.2020.02261

6. Leshner AI, Mancher M, editors. Medications for Opioid Use Disorder Save Lives. Washington, D.C.: National Academies Press; 2019. doi:10.17226/25310

7. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. Ann Intern Med. 2018;169: 137–145. doi:10.7326/M17-3107

8. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. 2021. Available: https://www.samhsa.gov/data

9. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011;41: 431–439. doi:10.1016/j.jsat.2011.06.005

10. Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend. 2016;160: 112–118. doi:10.1016/j.drugalcdep.2015.12.031

11. Bosanac EM, Parkinson RC, Hall DS. Geographic Access to Hospital Care: A 30-Minute Travel Time Standard: Med Care. 1976;14: 616–624. doi:10.1097/00005650-197607000-00006

12. Brustrom JE, Hunter DC. Going the distance: how far will women travel to undergo free mammography? Mil Med. 2001;166: 347–349.

13. Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V, Wang EA. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. JAMA Netw Open. 2022;5: e227028. doi:10.1001/jamanetworkopen.2022.7028

14. Friedmann PD, Lemon SC, Stein MD. Transportation and retention in outpatient drug abuse treatment programs. J Subst Abuse Treat. 2001;21: 97–103. doi:10.1016/s0740-5472(01)00185-4

15. Knudsen HK, Roman PM. Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders. J Addict Med. 2012;6: 280–286. doi:10.1097/ADM.0b013e318262a97a

16. Elwy AR, Ranganathan G, Eisen SV. Race-ethnicity and diagnosis as predictors of outpatient service use among treatment initiators. Psychiatr Serv Wash DC. 2008;59: 1285–1291. doi:10.1176/ps.2008.59.11.1285

17. Snowden LR, Pingitore D. Frequency and scope of mental health service delivery to African Americans in primary care. Ment Health Serv Res. 2002;4: 123–130. doi:10.1023/a:1019709728333

18. Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care. 1981;19: 127–140. doi:10.1097/00005650-198102000-00001

19. Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198: 80–86. doi:10.1016/j.drugalcdep.2019.01.037

20. Talen E, Anselin L. Assessing Spatial Equity: An Evaluation of Measures of Accessibility to Public Playgrounds. Environ Plan Econ Space. 1998;30: 595–613. doi:10.1068/a300595

21. Heil SH, Sigmon SC, Jones HE, Wagner M. Comparison of Characteristics of Opioid-Using Pregnant Women in Rural and Urban Settings. Am J Drug Alcohol Abuse. 2008;34: 463–471. doi:10.1080/00952990802122358

22. Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46: 273–288. doi:10.1080/00952990.2019.1694536

23. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States. J Environ Public Health. 2011;2011: 1–10. doi:10.1155/2011/948789

24. Amiri S, Lutz R, Socías ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93: 26–30. doi:10.1016/j.jsat.2018.07.006

25. Ridgway JP, Almirol EA, Schmitt J, Schuble T, Schneider JA. Travel Time to Clinic but not Neighborhood Crime Rate is Associated with Retention in Care Among HIV-Positive Patients. AIDS Behav. 2018;22: 3003–3008. doi:10.1007/s10461-018-2094-5

26. Lempert RJ. Robust Decision Making (RDM). In: Marchau VAWJ, Walker WE, Bloemen PJTM, Popper SW, editors. Decision Making under Deep Uncertainty: From Theory to Practice. Cham: Springer International Publishing; 2019. pp. 23–51. doi:10.1007/978-3-030-05252-2_2

27. Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME. Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. Kaderali L, editor. PLOS ONE. 2015;10: e0137993. doi:10.1371/journal.pone.0137993

28. Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study. J Acquir Immune Defic Syndr 1999. 2007;45: 108–114. doi:10.1097/QAI.0b013e318050d260

29. Lansky A, Abdul-Quader AS, Cribbin M, Hall T, Finlayson TJ, Garfein RS, et al. Developing an HIV Behavioral Surveillance System for Injecting Drug Users: The National HIV Behavioral Surveillance System. Public Health Rep. 2007;122: 48–55.

30. Mackesy-Amiti ME, Boodram B, Spiller MW, Paz-Bailey G, Prachand N, Broz D, et al. Injection-Related Risk Behavior and Engagement in Outreach, Intervention and Prevention Services Across 20 US Cities. J Acquir Immune Defic Syndr. 2017;75 Suppl 3: S316–S324. doi:10.1097/QAI.0000000000001406

31. Boodram B, Mackesy-Amiti M-E, Latkin C. The role of social networks and geography on risky injection behaviors of young persons who inject drugs. Drug Alcohol Depend. 2015;154: 229–235. doi:10.1016/j.drugalcdep.2015.06.042

32. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, et al. Trends in the Population Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992–2007. Khudyakov YE, editor. PLoS ONE. 2013;8: e64789. doi:10.1371/journal.pone.0064789

33. Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. J Urban Health Bull N Y Acad Med. 2018;95: 71–82. doi:10.1007/s11524-017-0185-7

34. Corsi KF, Lehman WK, Booth RE. The effect of methadone maintenance on positive outcomes for opiate injection drug users. J Subst Abuse Treat. 2009;37: 120–126. doi:10.1016/j.jsat.2008.11.004

35. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3: e1920622. doi:10.1001/jamanetworkopen.2019.20622

36. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. R J. 2018;10: 439–446.

37. Blanchard T, Matthews T. Retail Concentration, Food Deserts, and Food Disadvantaged Communities in Rural America. Remaking the North American Food System: Strategies for Sustainability. University of Nebraska Press; 2009.

38. Jiao J, Moudon AV, Ulmer J, Hurvitz PM, Drewnowski A. How to Identify Food Deserts: Measuring Physical and Economic Access to Supermarkets in King County, Washington. Am J Public Health. 2012;102: e32–e39. doi:10.2105/AJPH.2012.300675

39. Schmitt SK, Phibbs CS, Piette JD. The influence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatment. Addict Behav. 2003;28: 1183–1192. doi:10.1016/S0306-4603(02)00218-6

40. Home - SAMHSA Behavioral Health Treatment Services Locator. [cited 2 May 2022]. Available: https://findtreatment.samhsa.gov/

41. Ozik J, Collier NT, Wozniak JM, Spagnuolo C. From desktop to Large-Scale Model Exploration with Swift/T. 2016 Winter Simulation Conference (WSC). 2016. pp. 206–220. doi:10.1109/WSC.2016.7822090

42. Iloglu S, Joudrey PJ, Wang EA, Thornhill TA, Gonsalves G. Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis. Drug Alcohol Depend. 2021;220: 108534. doi:10.1016/j.drugalcdep.2021.108534

43. Joudrey PJ, Edelman EJ, Wang EA. Methadone for Opioid Use Disorder-Decades of Effectiveness but Still Miles Away in the US. JAMA Psychiatry. 2020;77: 1105–1106. doi:10.1001/jamapsychiatry.2020.1511

44. Boodram B, Mackesy-Amiti ME, Khanna A, Brickman B, Dahari H, Ozik J. People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination. PLOS ONE. 2022;17: e0248850. doi:10.1371/journal.pone.0248850

Figure 1. Spatial access to methadone providers for the actual scenario and three counterfactual distribution scenarios, under varying travel distance preference assumptions. Each dot represents the location of a single methadone provider. City of Chicago and collar county borders are indicated. Spatial access to methadone providers is calculated as distance to nearest provider to the center of each zip code area; thus in the low travel distance preference assumption, zip codes areas are not identified as accessible if there is no provider within a mile of its geographic center.

Figure 2. Syringe sharing episode reduction by zip code for each scenario under each reasonable access assumption. Syringe sharing reduction in each zip code under each reasonable access assumption for the actual scenario along with how the syringe sharing reduction changes if the methadone providers are spatially redistributed in counterfactual scenarios. Blue colored zip codes indicates that the counterfactual scenario has more reduction than the actual scenario (for the same zip code), while red colored zip codes indicate that the counterfactual scenario has less reduction than the actual scenario.

Figure 3. Regret score of annual reduction in needle sharing by reasonable access assumption and spatial distribution of methadone providers. Each dot represents the regret score for each of the 18 reasonable access assumptions. The regret score is defined as how many fewer syringe sharing episodes the scenario under consideration had compared to the best scenario under a particular reasonable access assumption.

Table 1. Travel distance to methadone provider preferences used for reasonable geographic access assumptions. The table represents six different possible combinations of low, medium, and high travel distance preferences considering three urban/suburban distance preference combinations for each low, medium, high distance preference pair with a maximum distance limit, and three corresponding low, medium, and high distance preference pairs with no maximum distance limit.

Travel Distance Preference	Travel Distance to Methadone Provider (miles)					
	With Maximum Distance Limit			No Maximum Distance Limit		
	Urban	Suburb/Rural		Urban	Suburb/Rural	
Low	1 (max: 15)	5 (max: 60)		1	5	
Medium	2 (max: 15)	10 (max: 60)		2	10	
High	5 (max: 15)	20 (max: 60)		5	20	

Appendix

Table A1. Overall syringe sharing reduction and regret scores under for each reasonable access assumption under each scenario

		Max dist threshold	Needle sharing reduction				Best (max)	Regret score			
Threshold	Penalty		Actual	S1	S2	S3		RS_Actual	RS_S1	RS_S2	RS_S3
1/5	0.6	F	870K	429K	943K	1,013K	1,013K	143K	584K	70K	0K
1/5	0.6	T	870K	429K	943K	1,016K	1,016K	146K	587K	73K	0K
1/5	0.75	F	895K	486K	972K	1,043K	1,043K	148K	557K	71K	0K
1/5	0.75	T	902K	486K	972K	1,034K	1,034K	132K	548K	62K	0K
1/5	0.9	F	985K	656K	1,036K	1,097K	1,097K	112K	441K	61K	0K
1/5	0.9	T	980K	656K	1,036K	1,087K	1,087K	107K	431K	51K	0K
2/10	0.6	F	1,014K	713K	1,108K	1,050K	1,108K	94K	395K	0K	58K
2/10	0.6	T	1,007K	713K	1,108K	1,062K	1,108K	101K	395K	0K	46K
2/10	0.75	F	1,016K	734K	1,120K	1,063K	1,120K	103K	385K	0K	57K
2/10	0.75	T	1,020K	734K	1,120K	1,063K	1,120K	100K	385K	0K	56K
2/10	0.9	F	1,050K	823K	1,117K	1,078K	1,117K	66K	294K	0K	39K
2/10	0.9	T	1,045K	823K	1,117K	1,076K	1,117K	72K	294K	0K	41K
5/20	0.6	F	1,059K	807K	1,073K	1,042K	1,073K	14K	266K	0K	30K
5/20	0.6	T	1,061K	807K	1,073K	1,044K	1,073K	11K	266K	0K	29K
5/20	0.75	F	1,062K	826K	1,079K	1,052K	1,079K	17K	254K	0K	27K
5/20	0.75	T	1,071K	826K	1,079K	1,047K	1,079K	8K	254K	0K	32K
5/20	0.9	F	1,065K	896K	1,083K	1,060K	1,083K	18K	187K	0K	23K
5/20	0.9	T	1,072K	896K	1,083K	1,053K	1,083K	10K	187K	0K	30K
							75th percentile RS	111K	439K	58K	40K

Overall Needle Sharing Reduction (Enrollment 90% comapred to Enrollment 0%) & Regret Scores

Table A1 shows the syringe sharing reduction outcome for each reasonable access assumption under each scenario, along with regret scores. For example, when the ideal geographical travel distance preference is set to be low (i.e., 1 mile for urban and 5 miles for suburban), penalty equals to 0.6, and we do not set a maximum limit, Scenario 3 generates the most syringe sharing reduction (1,013K, see first row in Table A1). Accordingly, the regret score for each other scenario is the difference between their syringe sharing reduction result and Scenario 3. In this case, Scenario 1 generates the largest regret score, meaning we expect the syringe sharing reduction to be the lowest in this case. In the last row of Table A1, we report the 75th percentile of regret scores across each of the18 reasonable access assumptions for each scenario, from which we observe that the two *Need-based* scenarios (Scenario 2 and Scenario 3) perform the best. Notably, the *Actual* scenario performs worse than the two *Need-based* scenarios but better than the *Random* scenario.

Table A2. Overall syringe sharing reduction relative risk and regret scores for each reasonable access assumption under each scenario

				Overall Needle Sharing Reduction Relative Risk (Enrollment 90%/Enrollment 0%, zip code weighted by Enrollment 0%)								
exp		Penalty	Threshold	Actual	S1	S2	S3	Best (min)	RS_Actual	RS_S1	RS_S2	RS_S3
1		0.6	1/5	0.567	0.786	0.530	0.495	0.495	0.071	0.291	0.035	0.000
2		0.6	2/10	0.495	0.645	0.448	0.477	0.448	0.047	0.197	0.000	0.029
3		0.6	5/20	0.472	0.598	0.466	0.481	0.466	0.007	0.132	0.000	0.015
4	No Max Distance Threshold	0.75	1/5	0.554	0.758	0.516	0.480	0.480	0.074	0.278	0.035	0.000
5		0.75	2/10	0.494	0.634	0.442	0.470	0.442	0.052	0.192	0.000	0.028
6		0.75	5/20	0.471	0.589	0.462	0.476	0.462	0.009	0.126	0.000	0.014
7		0.9	1/5	0.509	0.673	0.484	0.453	0.453	0.056	0.220	0.030	0.000
8		0.9	2/10	0.477	0.590	0.444	0.463	0.444	0.033	0.146	0.000	0.019
9		0.9	5/20	0.469	0.554	0.461	0.472	0.461	0.009	0.093	0.000	0.011
10		0.6	1/5	0.567	0.786	0.530	0.494	0.494	0.073	0.293	0.036	0.000
11		0.6	2/10	0.498	0.645	0.448	0.471	0.448	0.050	0.197	0.000	0.023
12	Max 15/60 miles Distance Threshold	0.6	5/20	0.471	0.598	0.466	0.480	0.466	0.006	0.132	0.000	0.014
13		0.75	1/5	0.550	0.758	0.516	0.485	0.485	0.066	0.273	0.031	0.000
14		0.75	2/10	0.492	0.634	0.442	0.470	0.442	0.050	0.192	0.000	0.028
15		0.75	5/20	0.466	0.589	0.462	0.478	0.462	0.004	0.126	0.000	0.016
16		0.9	1/5	0.512	0.673	0.484	0.459	0.459	0.053	0.215	0.025	0.000
17		0.9	2/10	0.479	0.590	0.444	0.464	0.444	0.036	0.146	0.000	0.020
18		0.9	5/20	0.466	0.554	0.461	0.475	0.461	0.005	0.093	0.000	0.015
								75th percentile RS	0.055	0.219	0.029	0.020

Note. RS represents regret score.